PRAC Takes a Closer Look at Anti-Cancer/Skin Drug

Drug Industry Daily
A A
The EMA’s Pharmacovigilance Risk Assessment Committee is considering recommending more rigorous patient screening before starting treatment with a common family of anti-cancer and topical skin cream drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily